225 studies found for:    Open Studies | "Triplets"
Show Display Options
Rank Status Study
1 Recruiting Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)
Conditions: Breast Tumor;   Breast Cancer;   Cancer of the Breast;   Estrogen Receptor- Negative Breast Cancer;   HER2- Negative Breast Cancer;   Progesterone Receptor- Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer;   Triple-negative Metastatic Breast Cancer;   Metastatic Breast Cancer
Interventions: Drug: nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects;   Drug: Carboplatin AUC 2;   Drug: gemcitabine 1000 mg
2 Recruiting GDC-0941 and Cisplatin in Treating Patients With Androgen Receptor-Negative Triple Negative Metastatic Breast Cancer
Conditions: Estrogen Receptor Negative Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast;   Triple Negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI;   Drug: GDC -0941
3 Not yet recruiting Safety and Immunogenicity of a Personalized Polyepitope DNA Vaccine Strategy in Breast Cancer Patients With Persistent Triple-Negative Disease Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple-Negative Breast Cancer;   Triple Negative Breast Neoplasms
Intervention: Biological: Personalized polyepitope DNA vaccine
4 Not yet recruiting Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
Conditions: Triple Negative Breast Cancer;   Triple Negative Breast Neoplasms;   Triple-Negative Breast Cancer
Interventions: Biological: Personalized synthetic long peptide vaccine (Poly ICLC);   Drug: Poly ICLC
5 Recruiting Patient-derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Other: Chemotherapy
6 Recruiting Cisplatin vs Paclitaxel for Triple Neg BRCA
Condition: Triple Negative Breast Cancer
Interventions: Drug: Cisplatin;   Drug: Paclitaxel
7 Unknown  Study to Identify Molecular Mechanisms of Clinical Resistance to Chemotherapy in Triple Negative Breast Cancer Patients
Condition: Triple Negative Breast Cancer
Interventions: Procedure: Needle core biopsies;   Procedure: Needle core biopsies of metastatic lesion
8 Not yet recruiting Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer
Condition: Triple-negative Breast Cancer
Interventions: Drug: IMMU-132 infusion is administered to participants in one arm for the study;   Drug: IMMU-132 plus Carboplatin infusion
9 Unknown  Comparison Study of Neoadjuvant Paclitaxel Plus Carboplatin/Epirubicin Treatment in Triple-negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Paclitaxel plus carboplatin;   Drug: Paclitaxel and epirubicin
10 Recruiting Metronomic Chemotherapy of Capecitabine After Standard Adjuvant Chemotherapy in Operable Triple Negative Breast Cancer
Conditions: Breast Cancer;   Capecitabine;   Triple Negative Breast Cancer
Intervention:
11 Recruiting Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer
Condition: Metastatic gpNMB Over-expressing Triple Negative Breast Cancer.
Interventions: Drug: CDX-011;   Drug: Capecitabine
12 Unknown  Comparison Study of Adjuvant Chemotherapy for Chinese Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Intervention: Drug: Paclitaxel Cisplatin
13 Recruiting A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
Condition: Triple Negative Breast Cancer
Interventions: Drug: Veliparib;   Drug: Carboplatin;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Placebo
14 Unknown  Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients
Condition: Triple Negative Local Advanced Breast Cancer
Intervention: Drug: docetaxel oxaliplatin
15 Recruiting Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer
Condition: Metastatic Triple Negative Breast Cancer
Intervention: Drug: Combination of Veliparib + Lapatinib
16 Recruiting Comparison of Biological Features Between pN0 Triple Negative Breast Tumours With Size < or = 10 mm (pT1a/b) Versus pT1c T2 < or = 30 mm
Condition: Triple Negative Breast Cancers Without Lymph-node Involvement and < or = 30 mm
Intervention: Procedure: Blood samples of 10 mL
17 Recruiting NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer
Conditions: Breast Cancer;   Triple Negative Breast Cancer
Intervention: Drug: Everolimus
18 Recruiting Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity
Condition: Triple Negative Breast Neoplasms
Interventions: Drug: Docetaxel;   Drug: Carboplatin
19 Recruiting Collecting, Analyzing, and Storing Samples From Patients With Metastatic, Triple Negative Breast Cancer Receiving Cisplatin
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Intervention: Other: laboratory biomarker analysis
20 Not yet recruiting Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
Condition: Triple Negative Breast Cancer
Intervention: Drug: GTx-024

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years